A carregar...
Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans
Fexuprazan is a new drug candidate in the potassium-competitive acid blocker (P-CAB) family. As proton pump inhibitors (PPIs), P-CABs inhibit gastric acid secretion and can be used to treat gastric acid-related disorders such as gastroesophageal reflux disease (GERD). Physiologically based pharmacok...
Na minha lista:
| Publicado no: | Pharmaceutics |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8229463/ https://ncbi.nlm.nih.gov/pubmed/34072547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13060813 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|